Is there a role for the assessment of health-related quality of life in the clinical evaluation of novel cytostatic agents?

Clinical Cancer Research

Volumn 9, Issue 6, 2003, Pages 1990-1994

  Patrick Miller, Linda J ^a,b  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOSTATIC AGENT; GEFITINIB;

CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CYTOTOXICITY; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; HEAD AND NECK CANCER; HUMAN; LUNG NON SMALL CELL CANCER; META ANALYSIS; OVARY CANCER; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; REVIEW; SURVIVAL TIME; TOXICITY; TOXICITY TESTING; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; HEALTH STATUS; HUMANS; LUNG NEOPLASMS; QUALITY OF LIFE; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 0037501314     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. LoRusso, P. M., Herbst, R. S., Rischin, D., Ranson, M., Calvert, H., Raymond, E., Kieback, D., Kaye, S., Gianni, L., Harris, A., and et al. Improvements in quality of life and disease-related symptoms in Phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors. Clin. Cancer Res., 9: 2040-2048, 2003.
2. Herbst, R. S., Maddox, A. M., Rothenberg, M. L., Small, E. J., Rubin, E. H., Baselga, J., Rojo, F., Hong, W. K., Swaisland, H., Averbuch, S. D., Ochs, J., and LoRusso, P. M. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J. Clin. Oncol., 20: 3815-3825, 2002.
3. Douillard, J-Y., Giaccone, G., Horai, T., Noda, K., Vansteenkiste, J. F., Takata, I., Gatzemeier, U., Fukuoka, M., Macleod, A., Feyereislova, A., Averbuch, S., Nogi, Y., Heyes, A., and Baselga, J. Improvement in disease-related symptoms and quality of life in patients with advanced non-small-cell lung cancer (NSCLC) treated with ZD1839 ('Iressa') (IDEAL 1). Proc. Am. Soc. Clin. Oncol. Annu. Meet., 21: 299a, 2002.
4. Natale, R. B., Skarin, A. T., Maddox, A-M., Hammond, L. A., Thomas, R., Gandara, D. R., Gerstein, H., Panella, T. J., Cole, J., Jahanzeb, M., Kash, J., Hamm, J., Langer, C. J., Saleh, M., Stella, P. J., Heyes, A., Helms, L., Ochs, J., Averbuch, S., Wolf, M, and Kay, A. Improvement in symptoms and quality of life for advanced non-small-cell lung cancer patients receiving ZD1839 ('Iressa') in IDEAL 2. Proc. Am. Soc. Clin. Oncol. Annu. Meet., 21: 292a, 2002.
5. rd Ed.), pp. 1-15. New York: Springer-Verlag, 1998.
6. Therese, P., Arbuck, S. G., Esienhouer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., and Gwyther, S. G. New guidelines to evaluate the response to treatment in solid tumors: European Organizations for Research and Treatment of Cancer, National Cancer Institute of the United States and National Cancer Institute of Canada. J. Natl. Cancer Inst., 92: 205-216, 2000.
7. Korn, E. L. Arbuck, S. G., Pluda, J. M., Simon, R., Kaplan, R. S., and Christian, M. C. Clinical trial designs for cytostatic agents: are new approaches needed? J. Clin. Oncol., 19: 265-272, 2001.
8. Gelmon, K. A., Eisenhauer, E. A., Harris, A. L., Ratain, M. J., and Workman, P. Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development? J. Natl. Cancer Inst., 91: 1281-1287, 1999.
9. Stadler, W. M., and Ratain, M. J. Development of target-based antineoplastic agents. Investig. New Drugs, 18: 7-16, 2000.
10. Arceci, R. J. Testing new agents: can we move beyond DLT? J. Pediat. Hematol. Oncol., 24: 83, 2002.
11. Johnson, J. R., Williams, G., and Pazdur, R. J. End points and United States Food and Drug Administration approval of oncology drugs. J. Clin. Oncol., 21: 1404-1411, 2003.
12. Johnson, J. R., and Temple, R. Food and Drug Administration requirements for approval of anti-cancer drugs. Cancer Treatment Report, 69: 1155-1159, 1985.
13. Nuland, S. B., Doctors: The Biography of Medicine. New York: Random House, 1989.
14. Bernhard, J., Gusset, H., and Humy, C. Practical issues in quality of life assessment in multicentre trials conducted by the Swiss Group for Clinical Cancer Res. Statistics in Medicine, 17: 633-639, 1998.
15. Finkelstein, D. M., Cassileth, B. R., Bonomi, P. D., Ruckdeschel, J. C., Ezdinli, E. Z., and Wolter, J. M. A pilot study of the Functional Living Index-Cancer (FLIC) Scale for the assessment of quality of life for metastatic lung cancer patients. An Eastern Cooperative Oncology Group study. Am. J. Clin. Oncol., 11: 630-633, 1988.
16. Osoba, D. The Quality of Life Committee of the Clinical Trials Group of the National Cancer Institute of Canada: organization and functions. Quality Life Res., 1: 211-218, 1992.
17. Jacobsen, P. B., Davis, K., and Cella, D. Assessing quality of life in research and clinical practice. Oncology, 16(Suppl.): 133-139, 2002.
18. Cheng, J. D., Hitt, J., Koczwara, B., Schulman, K. A., Burnett, C. B., Gaskin, D. J., Rowland, J. H., and Meropol, N. J. Impact of quality of life on patient expectations regarding phase I clinical trials. J. Clin. Oncol., 18: 421-428, 2000.
19. Osoba, D. What has been learned from measuring health-related quality of life in clinical oncology. Eur. J. Cancer, 35: 1565-1570, 1999.
20. Fayers, P. M., Hopwood, P., Harvey, A., Girling, D. J., Machin, D., and Stephens, R. Quality of life assessment in clinical trials-guidelines and a checklist for protocol writers: the U. K. Medical Research Council experience. MRC Cancer Trials Office. Eur. J. Cancer, 33: 20-28, 1997.
21. Casper, E. S., Green, M. R., Kelsen, D. P., Heelan, R. T., Brown, T. D., Flombaum, C. D., Trochanowski, B., and Tarassoff, P. G. Phase II trial of gemcitabine (2,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Investig. New Drugs, 12: 29-34, 1994.
22. Burris, H. A., 3rd., Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M. R., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P., Nelson, R., Dorr, F. A., Stephens, C. D., and Von Hoff. D. D. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol., 15: 2403-2413, 1997.
23. Guyatt, G. H., Osoba, D., Wu, A. W., Wyrwich, K. W., and Norman, G. R. Clinical Significance Consensus Meeting Group. Methods to explain the clinical significance of health status measures. Mayo Clin. Proc., 77: 371-383, 2002.
24. Cella, D., Bullinger, M., Scott, C., and Barofsky, I. Clinical Significance Consensus Meeting Group. Group vs individual approaches to understanding the clincial significance of differences of changes in quality of life data Mayo Clin. Proc., 77: 384-392, 2002.
25. Cella, D., Eton, D. T., Fairclough, D. L., Bonomi, P., Heyes, A. E., Silberman, C., Wolf, M. K., and Johnson, D. H. What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) Questionnaire?. Results from Eastern Cooperative Oncology Group (ECOG) Study 5592. J. Clin. Epidemiol., 55: 285-295, 2002.
26. Hurny, C., Bernhard, J., Joss, R., Willems, Y., Cavalli, F., Kiser, J., Brunner, K., Favre, S., Alberto, P., Glaus, A., and et al. Feasibility of quality of life assessment in a randomized phase III trial of small cell lung cancer-a lesson from the real world-the Swiss Group for Clinical Cancer Res. SAKK. Ann. Oncol., 3: 825-831, 1992.
27. Hayden, K. A., Moinpour, C. M., Metch, B., Feigl, P., O'Bryan, R. M., Green, S., and Osborne, C. K. Pitfalls in quality-of-life assessment: lessons from a Southwest Oncology Group breast cancer clinical trial. Oncol. Nurs. Forum, 20: 1415-1419, 1993.
28. Hahn, E. A., Webster, K. A., Cella, D., and Fairclough, D. L. Missing data in quality of life research in Eastern Cooperative Oncology Group (ECOG) clinical trials: problems and solutions. Stat. Med., 17: 547-559, 1998.
29. Fairclough, D. L., Peterson, H. F., Cella, D., and Bonomi, P. Comparison of several model-based methods for analysing incomplete quality of life data in cancer clinical trials. Stat. Med., 17: 781-796, 1998.
30. Troxel, A. B., Fairclough, D. L., Curran, D., and Hahn, E. A. Statistical analysis of quality of life with missing data in cancer clinical trials. Stat. Med., 17: 653-666, 1998.
31. Sprangers, M. A., Moinpour, C. M., Moynihan, T. J., Patrick, D. L., and Revicki, D. A. Clinical Significance Consensus Meeting Group. Assessing meaningful change in quality of life over time: a users' guide for clinicians. Mayo Clin. Proc., 77: 561-571, 2002.
32. Julious, S. A., Campbell, M. J., Walker, S. J., George, S. L., and Machin, D. Sample sizes for cancer trials where Health Related Quality of Life is the primary outcome. Br. J. Cancer, 83: 959-963, 2000.
33. Wilson, K. A., Dowling, A. J., Abdolell, M., and Tannock, I. F. Perception of quality of life by patients, partners and treating physicians. Quality Life Res., 9: 1041-1052, 2000.
34. Nekolaichuk, C. L., Bruera, E., Spachynski, K., MacEachern, T., Hanson, J., and Maguire, T. O. A comparison of patient and proxy symptom assessments in advanced cancer patients. Palliat. Med., 13: 311-323, 1999.
35. Stephens, R. J., Hopwood, P., Girling, D. J., and Machin, D. Randomized trials with quality of life endpoints: are doctors' ratings of patients' physical symptoms interchangeable with patients' self-ratings? Quality Life Res., 6: 225-236, 1997.
36. Efficace, F., and Bottomemly, A. Do quality-of-life randomized clinical trials support clinicians in their decision-making?. J. Clin. Oncol., 21: 4126, 2003.
37. Sloan, J. A., Cella, D., Frost, M., Guyatt, G. H., Sprangers, M., and Symonds, T. Clinical Significance Consensus Meeting Group. Assessing clinical significance in measuring oncology patient quality of life: introduction to the symposium, content overview, and definition of terms. Mayo Clin. Proc., 77: 367-370, 2002.
38. Aaronson, N. K., Meyerowitz, B. E., Bard, M., Bloom, J. R., Fawzy, F. I., Feldstein, M., Fink, D., Holland, J. C., Johnson, J. E., Lowman, J. T., and et al. Quality of life research in oncology. Past achievements and future priorities. Cancer (Phila.), 67: 839-843, 1991.
39. Johnson, J. R. A regulatory view. In: S. R. Walker, and R. M. Rosser (eds.). Quality of life assessment: key issues in the 1990s, pp. 393-400. Boston: Kluwer, 1992.
40. Nayfield, S. G., Ganz, P. A., Moinpour, C. M., Cella, D. F., and Hailey, B. J. Report from a National Cancer Institute (USA) workshop on quality of life assessment in cancer clinical trials. Quality Life Res., 1: 203-210, 1992.
41. Gotay, C. C., Korn, E. L., McCabe, M. S., Moore, T. D., and Cheson, B. D. Quality-of-life assessment in cancer treatment protocols: Research issues in protocol development. J. Natl. Cancer Inst., 84: 575-579, 1992.
42. Cella, D. F., and Bonomi, A. E. Measuring quality of life: 1995 update. Oncology (Huntington). 9(Supp.): 47-60, 1995.
43. Bernhard, J., Cella, D. F., Coates, A. S., Fallowfield, L., Ganz, P. A., Moinpour, C. M., Mosconi, P., Osoba, D., Simes J., and Hurny, C. Missing quality of life data in cancer clinical trials: serious problems and challenges. Stat. Med., 17: 517-532, 1998.
44. Sloan, J. A. Quality of life meta-analysis: why treat it differently? J. Clin. Oncol., 21: 1422, 2003.